Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Pulmatrix, Inc.

Market Cap 5.11M 4.42M 4.07M 3.81M 7.14M 486M 7.25M 48.05M 18.74M 237M 19.19M 18.78M 819M P/E Ratio 2024
-2.67x
P/E Ratio 2025 -1.58x
Enterprise Value 1.03M 885K 816K 764K 1.43M 97.45M 1.45M 9.63M 3.76M 47.43M 3.85M 3.77M 164M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.26%
Yield 2024 *
-
Yield 2025 -
1 day+1.45%
1 week+5.26%
Current month+0.72%
1 month+10.24%
3 months-33.65%
6 months-69.43%
Current year-37.22%
1 week 1.28
Extreme 1.2801
1.55
1 month 1.22
Extreme 1.22
1.55
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
9.15
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
22.19
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 2024-07-19
Director TitleAgeSince
Director/Board Member 58 2019-10-31
Director/Board Member 57 2020-06-22
Director/Board Member 55 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
23-01-25Free

Director

1,700 0.0467%
23-01-25Free

Chief Financial Officer

9,900 0.2720%
23-01-25Free

Director

1,700 0.0467%
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%+5.26%-82.07%-47.57% 5.11M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.76%+2.41%+16.74%+89.53% 21.37B
Weighted average by Cap. +1.72%+2.37%+32.04%+99.59%

Financials

2024 2025
Net sales 7.81M 6.74M 6.21M 5.82M 10.9M 742M 11.07M 73.36M 28.6M 361M 29.3M 28.67M 1.25B -
Net income -9.56M -8.26M -7.61M -7.12M -13.35M -909M -13.55M -89.83M -35.03M -442M -35.87M -35.11M -1.53B -5.16M -4.46M -4.11M -3.85M -7.21M -491M -7.32M -48.51M -18.91M -239M -19.37M -18.96M -827M
Net Debt -9.52M -8.22M -7.58M -7.09M -13.29M -905M -13.5M -89.48M -34.89M -440M -35.73M -34.97M -1.53B -4.09M -3.53M -3.25M -3.05M -5.71M -389M -5.8M -38.42M -14.98M -189M -15.34M -15.02M -655M
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
26-06-12 1.400 $ +1.45% 23,651
26-06-11 1.380 $ +0.73% 12,287
26-06-10 1.370 $ -0.72% 3,016
26-06-09 1.380 $ -2.82% 46,341
26-06-08 1.420 $ +6.77% 141,743
  1. Stock Market
  2. Stocks
  3. PULM Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!